Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
Tadeusz Robak Huiqiang Huang; Jie Jim; Jun Shu; Ting Liu; Olga S Samailova; Juliana Pereira; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii A Osmanov; Julia Alexeeva; Jiri Mayer; Xiaonan Hong; Yoshiharu Maeda; Brendan Rooney; Helgi van de Velde; Franco Cavalli; Annual Meeting and Exposition / ASH 2014 (56. San Francisco/EUA
Blood New York v. 124, n. 21, res. 4412, suppl, 2014New York 2014
Acesso online. A biblioteca também possui exemplares impressos.
- 0
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
bcsep 611 2014
bcsep 586 2014
browse_callnumber
display.do?gathStatTab=true&dscnt=0&callNumberBrowseField=browse_callnumber&tabRealType=browseshelf&mode=Basic&vid=USP&rfnGrp=1&tab=default_tab&dstmp=1718638529649&rfnGrpCounter=1&fctV=Blood&callNumber=bcsep+608+2014&fctN=facet_jtitle&vl(freeText0)=Liu%2C%20Y.&ct=display&fn=search&indx=5&recIdxs=0&elementId=0
Página Inicial
RSS
Feed
Políticas
Fale Conosco-
Realização:
Logos de Redes Sociais: 